

1. Nayir E. Pathogenesis of bone metastasis. *J Oncol Sci.* 2016;1:13–6.
2. Bussard KM, Gay CV, Mastro AM. The bone microenvironment in metastasis; what is special about bone? *Cancer Metastasis Rev.* 2008;27(1):41–55.
3. Coleman R, Rubens R. The clinical course of bone metastases from breast cancer. *Br J Cancer.* 1987;55(1):61–6.
4. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. *Nat Rev Cancer.* 2002;2(8):584–93.
5. Narayanan P. Denosumab: A comprehensive review. *South Asian J Cancer.* 2013;2(4):272–7.
6. Roodman GD. Mechanisms of Bone Metastasis. *N Engl J Med.* 2004;350(16):1655–64.
7. Chung P-L, Zhou S, Eslami B, Shen L, LeBoff MS, Glowacki J. Effect of age on regulation of human osteoclast differentiation. *J Cell Biochem.* 2014;115(8):1412–9.
8. Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, dkk. Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab. *Nat Rev Drug Discov.* 2012;11(5):401–19.
9. Huang L, Cheng Y, Chow L, Zheng M, Kumta S. Tumour cells produce receptor activator of NF- κ B ligand (RANKL) in skeletal metastases. *J Clin Pathol.* 2002;55(11):876–879.
10. Kitazawa S, Kitazawa R. RANK ligand is a prerequisite for cancer-associated osteolytic lesions. *J Pathol.* 2002;198(2):228–36.
11. Raggatt LJ, Partridge NC. Cellular and Molecular Mechanisms of Bone Remodeling. *J Biol Chem.* 2010;285(33):25103–8.
12. Boyce BF, Xing L, Shakespeare W, Wang Y, Dalgarno D, Iuliucci J, dkk. Regulation of bone remodeling and emerging breakthrough drugs for osteoporosis and osteolytic bone metastases. *Kidney Int Suppl.* 2003;63(85):S2–5.
13. Liu W, Zhang X. Receptor activator of nuclear factor- κ B ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (Review). *MI Med Rep.* 2015;11(5):3212–8.

14. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang M-S, Lüthy R, dkk. Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density. *Cell*. 1997;89(2):309–19.
15. Rodan GA, Martin TJ. Role of osteoblasts in hormonal control of bone resorption—A hypothesis. *Calcif Tissue Int*. 1981;33(4):349–51.
16. Tat SK, Pelletier J-P, Velasco CR, Padrines M, Martel-Pelletier J. New Perspective in Osteoarthritis: The OPG and RANKL System as a Potential Therapeutic Target? *Keio J Med*. 2009;58(1):29–40.
17. Mundy GR. Osteoporosis and Inflammation. *Nutr Rev*. 2008;65(12 Pt 2):S147–51.
18. Khosla S. Minireview: The OPG/RANKL/RANK System. *Endocrinology*. 142(12):5050–6.
19. Selvaggi G, Scagliotti GV. Management of bone metastases in cancer: A review. *Crit Rev Oncol Hematol*. 2005;56(3):365–78.
20. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. *Cancer Treat Rev*. 2001;27(3):165–76.
21. Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N, Pinto L, dkk. Bone metastases: an overview. *Oncol Rev*. 2017;11(1):321.
22. Coleman E, Seaman JJ. The Role of Zoledronic Acid in Cancer: Clinical Studies in the Treatment and Prevention of Bone Metastases. :6.
23. Roodman GD, Dougall WC. RANK ligand as a therapeutic target for bone metastases and multiple myeloma. *Cancer Treat Rev*. 2008;34(1):92–101.
24. Santini D, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A, dkk. Receptor Activator of NF- κ B (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients. Dent P, editor. *PLoS ONE*. 2011;6(4):e19234.
25. Santini D, Perrone G, Roato I, Godio L, Pantano F, Grasso D, dkk. Expression pattern of receptor activator of NF κ B (RANK) in a series of primary solid tumors and related bone metastases. *J Cell Physiol*. 2011;226(3):780–4.
26. Dougall WC, Holen I, González Suárez E. Targeting RANKL in metastasis. *Bonekey Rep*. 2014;3:519.

27. Findlay DM, Atkins GJ. Relationship between serum RANKL and RANKL in bone. *Osteoporos Int.* 2011;22(10):2597–602.
28. Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: mechanism of action and clinical outcomes: Denosumab: mechanism of action and clinical outcomes. *Int J Clin Pract.* 2012;66(12):1139–46.
29. Rajee N, Yee A. Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients. *Clin Interv Aging.* 2012;7:331–8.
30. Li S, Wang Y, Qi J, Qiu L. Clinical Features of Bone Complications and Prognostic Value of Bone Lesions Detected by X-ray Skeletal Survey in Previously Untreated Patients with Multiple Myeloma. *Indian J Hematol Blood Transfus.* 2010;26(3):83–8.
31. Vano Y-A, Oudard S, By M-A, Têtu P, Thibault C, Aboudagga H, dkk. Optimal cut-off for rasio neutrofil berbanding limfosit: Fact or Fantasy? A prospective cohort study in metastatic cancer patients. Coleman WB, editor. *PLoS ONE.* 6 April 2018;13(4):e0195042.
32. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. *Future Oncol.* 2010;6(1):149–63.
33. Hernandez RK, Wade SW, Reich A, Pirolli M, Liede A, Lyman GH. Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States. *BMC Cancer.* 2018;18:44.
34. Guthrie GJK, Charles KA, Roxburgh CSD, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer. *Crit Rev Oncol Hematol.* 2013;88(1):218–30.
35. Öztürk ZA, Yesil Y, Kuyumcu ME, Bilici M, Öztürk N, Yeşil NK, dkk. Inverse relationship between neutrophil lymphocyte ratio (NLR) and bone mineral density (BMD) in elderly people. *Archives of Gerontology and Geriatrics.* Juli 2013;57(1):81–5.
36. Ahn H, Lee K, Kim JM, Kwon SH, Lee SH, Lee SY, dkk. Accelerated Lactate Dehydrogenase Activity Potentiates Osteoclastogenesis via NFATc1 Signaling. Kim J-E, editor. *PLoS ONE.* 2016;11(4):1–13.
37. Rove KO, Crawford ED. Metastatic Cancer in Solid Tumors and Clinical Outcome: Skeletal-Related Events. *Oncology.* 2009;23(14 Suppl 5):21–7.

38. Virk MS, Lieberman JR. Tumor metastasis to bone. *Arthritis Res Ther*. 2007;9(Suppl 1):S5.
39. Peng X, Guo W, Ren T, Lou Z, Lu X, Zhang S, dkk. Differential Expression of the RANKL/RANK/OPG System Is Associated with Bone Metastasis in Human Non-Small Cell Lung Cancer. Samant R, editor. *PLoS ONE*. 2013;8(3):e58361.
40. Whang PG, Schwarz EM, Gamradt SC, Dougall WC, Lieberman JR. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone. *J Orthop Res*. November 2005;23(6):1475–83.
41. Cao J, Venton L, Sakata T, Halloran BP. Expression of RANKL and OPG Correlates With Age-Related Bone Loss in Male C57BL/6 Mice. *J Bone Miner Res*. 2003;18(2):270–7.
42. Roodman GD. Regulation of Osteoclast Differentiation. *Ann NY Acad Sci*. 2006;1068(1):100–9.
43. Conen K, Hagmann R, Hess V, Zippelius A, Rothschild SI. Incidence and predictors of Bone Metastases (BM) and Skeletal-Related Events (SREs) in Small Cell Lung Cancer (SCLC): A Swiss patient cohort. *J Cancer*. 2016;7(14):2110–6.
44. Katakami N, Kunikane H, Takeda K, Takayama K, Sawa T, Saito H, dkk. Prospective Study on the Incidence of Bone Metastasis (BM) and Skeletal-Related Events (SREs) in Patients (pts) with Stage IIIB and IV Lung Cancer—CSP-HOR 13. *J Thorac Oncol*. 2014;9(2):231–8.
45. Ibrahim T, Ricci M, Scarpi E, Bongiovanni A, Ricci R, Riva N, dkk. RANKL: A promising circulating marker for bone metastasis response. *Oncol Lett*. 2016;12(4):2970–5.
46. Caliskan B, Korkmaz AN. Can Neutrophil/Lymphocyte Ratio be a Predictor for Bone Metastases of Solid Tumors? *World J Nucl Med*. 2016;15(3):196–9.
47. Thio QCBS, Goudriaan WA, Janssen SJ, Paulino Pereira NR, Sciubba DM, Rosovsky RP, dkk. Prognostic role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with bone metastases. *Br J Cancer*. September 2018;119(6):737–43.
48. Huang C, Li S. Association of blood neutrophil lymphocyte ratio in the patients with postmenopausal osteoporosis. *Pak J Med Sci*. 2016;32(3):762–5.



UNIVERSITAS
GADJAH MADA

Korelasi Ekspresi mRNA RANKL dengan Profil Osteoklastik Pasien dengan Metastasis Adenocarcinoma pada

Tulang Panjang di RSUP Dr. Sardjito

IRENE ARANETA, Dr. dr. Rahadyan Magetsari, Sp. OT (K)

Universitas Gadjah Mada, 2020 | Diunduh dari <http://etd.repository.ugm.ac.id/>

49. Wang S, Zhang Z, Fang F, Gao X, Sun W, Liu H. The neutrophil/lymphocyte ratio is an independent prognostic indicator in patients with bone metastasis. *Oncology Letters*. Juli 2011;2(4):735–40.